BIND Therapeutics: Cowen and Company Healthcare Conference (BIND Therapeutics) - Mar 5, 2015 - “Phase 2 Data Provide Clear Differentiation from Docetaxel in KRAS Mutant NSCLC”; “Confirmed PRs: 2/9 patients Phase 2 (22%), 3/10 patients Phase 1 + 2 (30%)”; “Median response duration of 5.8 months”; “Disease control rate of 66%”; “Favorable safety profile”; “Compares favorably with the most advanced combination in phase 3 (docetaxel + selumetinib)”
P2 data • Non Small Cell Lung Cancer • Oncology
|